Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Single nucleotide polymorphisms (SNPs) in the multiple drug resistance protein 1 (MRP1) and P-glycoprotein 1 (MDR1) genes modulate their ability to mediate drug resistance. We therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients treated with bortezomib or bortezomib with pegylated liposomal doxorubicin (PLD). The MRP1/R723Q polymorphism was found in five subjects among the 279 patient study population, all of whom received PLD + bortezomib. Its presence was associated with a longer time to progression (TTP; median 330 vs. 129 days; p = 0.0008), progression-free survival (PFS; median 338 vs. 129 days; p = 0.0006), and overall survival (p = 0.0045). MDR1/3435(C > T), which was in Hardy-Weinberg equilibrium, showed a trend of association with PFS (p = 0.0578), response rate (p = 0.0782) and TTP (p = 0.0923) in PLD + bortezomib patients, though no correlation was found in the bortezomib arm. In a recessive genetic model, MDR1/3435 T was significantly associated with a better TTP (p = 0.0405) and PFS (p = 0.0186) in PLD + bortezomib patients. These findings suggest a potential role for MRP1 and MDR1 SNPs in modulating the long-term outcome of relapsed and/or refractory myeloma patients treated with PLD + bortezomib. Moreover, they support prospective studies to determine if such data could be used to tailor therapy to the genetic makeup of individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“One example is that of the immunomodulatory agent lenalidomide which, when combined with dexamethasone, is superior to corticosteroids alone [5, 6].”
BackgroundSelf-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“One example is that of the immunomodulatory agent lenalidomide which, when combined with dexamethasone, is superior to corticosteroids alone [5, 6].”
BackgroundKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationClinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Cited by
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Riganti, C., Voena, C., Kopecka, J., Corsetto, P. A., Montorfano, G., Enrico, E., Costamagna, C., Rizzo, A. M., Ghigo, D., & Bosia, A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2001389 · Cited by 86
Conseil, G., & Cole, S. P. C. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054213 · Cited by 28
“It is of interest that in a small phase III study of Caucasian patients with advanced multiple myeloma, the presence of the R723Q nsSNP in 5 of 279 patients being treated with bortezomib and pegylated liposomal doxorubicin was associated with a different overall response rate and durability (Buda et al., 2010).”
Background
Metadata
- Authors
- Buda, G., Ricci, D., Huang, C. C., Favis, R., Cohen, N., Zhuang, S. H., Harousseau, J.-L., Sonneveld, P., Bladé, J., & Orlowski, R. Z.
- Venue
- Annals of Hematology
- Published
- 2010-06-08
- Volume
- 89
- Issue
- 11
- Pages
- 1133-1140
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W2137480667
- Cited by
- 61
- References
- 4
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. https://app.cochat.ai/papers/10.1007/s00277-010-0992-3
- The paper
- Buda, G., Ricci, D., Huang, C. C., Favis, R., Cohen, N., Zhuang, S. H., Harousseau, J.-L., Sonneveld, P., Bladé, J., & Orlowski, R. Z. (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of Hematology. https://doi.org/10.1007/s00277-010-0992-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.